Shares of Second Sight Medical Products Inc. (NASDAQ:EYES) saw an uptick in trading volume on Thursday . 2,601,358 shares were traded during trading, an increase of 285% from the previous session’s volume of 675,624 shares.The stock last traded at $4.04 and had previously closed at $3.38.

Separately, Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Friday, June 24th.

The stock’s market capitalization is $147.75 million. The firm’s 50 day moving average is $3.76 and its 200 day moving average is $4.65.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings results on Thursday, April 28th. The medical device company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. During the same quarter in the previous year, the company posted ($0.12) earnings per share. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $1.38 million. The business’s revenue for the quarter was down 38.2% on a year-over-year basis. On average, analysts forecast that Second Sight Medical Products Inc. will post ($0.65) EPS for the current fiscal year.

In related news, Chairman Robert J. Greenberg sold 8,571 shares of the company’s stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total transaction of $35,141.10. Following the transaction, the chairman now directly owns 172,911 shares in the company, valued at approximately $708,935.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Robert J. Greenberg sold 8,223 shares of the company’s stock in a transaction dated Monday, April 18th. The shares were sold at an average price of $5.27, for a total transaction of $43,335.21. Following the transaction, the chairman now owns 181,134 shares in the company, valued at $954,576.18. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Zeke Capital Advisors LLC acquired a new stake in shares of Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, Holdings Channel reports. The fund acquired 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products accounts for 2.5% of Zeke Capital Advisors LLC’s portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned 1.38% of Second Sight Medical Products at the end of the most recent reporting period.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.